Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX)

Historical Holders from Q2 2014 to Q4 2025

Symbol
ALDX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
60,026,563
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
39,235,813
Holdings value
$204,754,193
% of all portfolios
0%
Number of holders
130
Number of buys
79
Number of sells
41
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PERCEPTIVE ADVISORS LLC 8.7% +27% $27,260,463 +$6,110,950 5,222,311 +29% Perceptive Advisors LLC 30 Sep 2025
As of 30 Sep 2025 Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 39,235,813 shares of 60,026,563 outstanding shares and own 65% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) own 58% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Knoll Capital Management, LLC 9.1% 5,475,516 0% 15% $28,582,193
PERCEPTIVE ADVISORS LLC 8.7% 5,222,311 +29% 0.8% $27,260,463
BlackRock, Inc. 6.3% 3,804,920 -1.2% 0% $19,861,683
VANGUARD GROUP INC 6% 3,591,869 +2.6% 0% $18,749,556
ARDSLEY ADVISORY PARTNERS LP 3.2% 1,900,000 -7.3% 1.5% $9,918,000
AQR CAPITAL MANAGEMENT LLC 2.5% 1,505,360 +2.1% 0.01% $7,857,980
D. E. Shaw & Co., Inc. 2.3% 1,379,843 +183% 0.01% $7,202,780
KINGDON CAPITAL MANAGEMENT, L.L.C. 2.2% 1,331,791 0% 1.1% $6,951,949
GEODE CAPITAL MANAGEMENT, LLC 2% 1,176,420 +2.6% 0% $6,142,220
KENNEDY CAPITAL MANAGEMENT LLC 1.9% 1,112,213 +62% 0.13% $5,805,752
STATE STREET CORP 1.8% 1,102,674 +4.4% 0% $5,755,958
MORGAN STANLEY 1.8% 1,083,319 +40% 0% $5,654,926
JACOBS LEVY EQUITY MANAGEMENT, INC 1.6% 947,551 +49% 0.02% $4,946,216
ACADIAN ASSET MANAGEMENT LLC 1.4% 835,811 +334% 0.01% $4,360,000
683 Capital Management, LLC 1.4% 820,000 -24% 0.39% $4,280,400
DIMENSIONAL FUND ADVISORS LP 1.1% 648,371 -9.8% 0% $3,384,462
NORTHERN TRUST CORP 0.68% 407,960 +0.99% 0% $2,129,551
BANK OF AMERICA CORP /DE/ 0.65% 390,078 +591% 0% $2,036,207
WELLS FARGO & COMPANY/MN 0.6% 361,469 -0.74% 0% $1,886,868
DEUTSCHE BANK AG\ 0.52% 314,728 +2.6% 0% $1,642,880
TWO SIGMA INVESTMENTS, LP 0.45% 273,054 +390% 0% $1,425,342
WOODSTOCK CORP 0.44% 266,756 0% 0.12% $1,392,466
JANE STREET GROUP, LLC 0.42% 251,518 +160% 0% $1,312,924
Palo Alto Investors LP 0.38% 225,465 0% 0.22% $1,176,927
UBS Group AG 0.33% 200,739 +87% 0% $1,047,857

Institutional Holders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 297 $1,538 -$3,920 $5.18 1
2025 Q3 39,235,813 $204,754,193 +$26,942,510 $5.22 130
2025 Q2 34,234,495 $131,165,420 -$14,803,182 $3.83 121
2025 Q1 37,522,553 $215,581,662 +$3,357,660 $5.75 124
2024 Q4 37,181,780 $185,566,183 +$2,534,433 $4.99 117
2024 Q3 36,411,204 $196,355,871 +$6,362,230 $5.39 111
2024 Q2 35,332,656 $116,899,840 -$329,270 $3.31 103
2024 Q1 35,411,236 $115,798,928 +$808,753 $3.27 101
2023 Q4 35,121,957 $123,276,317 -$16,780,776 $3.51 103
2023 Q3 37,775,090 $252,308,601 -$9,900,512 $6.68 120
2023 Q2 39,037,773 $327,514,881 +$24,184,461 $8.39 119
2023 Q1 35,585,837 $353,348,951 +$15,344,761 $9.93 107
2022 Q4 34,171,691 $237,833,495 -$18,830,170 $6.96 93
2022 Q3 36,966,565 $197,399,795 +$1,459,079 $5.34 85
2022 Q2 36,943,694 $147,408,805 -$7,357,330 $3.99 88
2022 Q1 38,636,557 $171,807,935 +$10,287,580 $4.44 102
2021 Q4 36,272,402 $145,130,796 -$44,887,818 $4.00 110
2021 Q3 39,720,964 $348,695,759 -$60,891,971 $8.78 114
2021 Q2 45,258,901 $512,794,552 +$153,473,538 $11.33 130
2021 Q1 31,692,851 $376,513,639 +$122,609,589 $11.88 107
2020 Q4 22,091,649 $151,541,784 -$10,169,396 $6.86 95
2020 Q3 23,807,765 $176,308,405 +$68,333,848 $7.41 84
2020 Q2 14,645,367 $61,066,116 -$6,590,170 $4.17 79
2020 Q1 16,769,610 $41,415,535 -$6,410,268 $2.47 69
2019 Q4 17,701,121 $102,840,148 +$1,433,085 $5.81 76
2019 Q3 16,864,477 $88,888,097 -$685,228 $5.27 70
2019 Q2 16,888,317 $101,327,468 +$1,168,639 $6.00 75
2019 Q1 16,361,337 $147,746,642 -$6,160,793 $9.03 77
2018 Q4 17,157,946 $141,481,000 -$15,993,709 $8.30 75
2018 Q3 18,046,261 $248,653,190 +$81,737,278 $13.80 90
2018 Q2 12,131,183 $96,444,142 +$14,632,796 $7.95 65
2018 Q1 10,285,308 $77,138,000 +$3,821,299 $7.50 42
2017 Q4 9,777,889 $66,488,000 +$3,712,599 $6.80 35
2017 Q3 9,221,517 $66,394,000 +$13,267,111 $7.20 35
2017 Q2 7,437,286 $34,736,000 -$2,554,099 $4.65 24
2017 Q1 7,897,813 $37,958,000 +$8,366,763 $5.00 24
2016 Q4 6,136,618 $32,831,000 +$111,606 $5.35 20
2016 Q3 6,112,780 $47,882,100 -$1,304,703 $7.82 22
2016 Q2 6,358,443 $36,177,450 +$11,374,826 $5.69 25
2016 Q1 4,372,667 $18,317,243 -$231,292 $4.19 26
2015 Q4 4,427,755 $30,018,000 +$376,484 $6.78 20
2015 Q3 4,330,050 $25,241,000 +$608,221 $5.83 22
2015 Q2 4,225,512 $32,853,000 +$19,634,402 $7.76 23
2015 Q1 1,691,795 $17,415,000 +$8,386,368 $10.18 15
2014 Q4 870,129 $6,277,000 +$82,000 $7.18 5
2014 Q3 859,337 $5,163,000 +$34,237 $5.74 6
2014 Q2 852,047 $5,639,000 +$5,638,000 $6.56 5